Aptus Capital Advisors LLC Acquires 1,429 Shares of Cencora, Inc. (NYSE:COR)

Aptus Capital Advisors LLC lifted its holdings in shares of Cencora, Inc. (NYSE:COR) by 117.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,647 shares of the company’s stock after acquiring an additional 1,429 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Cencora were worth $595,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in COR. JFS Wealth Advisors LLC increased its holdings in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after purchasing an additional 46 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in Cencora in the 4th quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC raised its holdings in Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after acquiring an additional 69 shares during the period. Kentucky Trust Co acquired a new stake in Cencora during the fourth quarter worth approximately $33,000. Finally, WASHINGTON TRUST Co boosted its holdings in shares of Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after acquiring an additional 46 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Trading Up 4.5 %

COR opened at $304.04 on Thursday. The company has a market cap of $58.96 billion, a P/E ratio of 43.25, a PEG ratio of 1.31 and a beta of 0.60. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The company’s 50 day moving average is $275.33 and its 200-day moving average is $252.65. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $309.35.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating analysts’ consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same quarter last year, the business posted $3.80 earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. Equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the transaction, the chief executive officer now owns 47,582 shares in the company, valued at approximately $13,766,900.06. The trade was a 9.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company’s stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,223 shares of company stock worth $13,580,967. 10.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

COR has been the topic of a number of recent research reports. UBS Group increased their target price on Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Evercore ISI lifted their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Finally, Bank of America increased their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a “neutral” rating in a research report on Friday, April 11th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $290.00.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.